Nuvation Bio (NUVB) Capital Expenditures (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Capital Expenditures of $48000.0 for Q1 2026, down 33.33% year-over-year from $72000.0 in Q1 2025, and up 100.63% quarter-over-quarter from -$7.6 million in Q4 2025.
Powered by 
Analysis
Nuvation Bio (NUVB) Capital Expenditures (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Capital Expenditures for 7 consecutive years, with $48000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 33.33% year-over-year to $48000.0; the TTM figure through Mar 2026 stood at $330000.0 (down 94.57% YoY), while the FY2025 annual figure was $354000.0, down 94.13% from the prior year.
- Capital Expenditures rose to $48000.0 in Q1 2026 per NUVB's latest filing, from -$7.6 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $8.1 million in Q3 2025 and bottomed at -$7.6 million in Q4 2025.
- Historically, Capital Expenditures has averaged $491000.0 across 5 years, with a median of $37500.0 in 2024.
- Annual changes were most pronounced in 2022 — Capital Expenditures slumped 796.55% — and 2024, when it soared 47107.69%.
- Nuvation Bio's Capital Expenditures stood at $370000.0 in 2022, then tumbled by 96.49% to $13000.0 in 2023, then jumped by 47107.69% to $6.1 million in 2024, then slumped by 224.59% to -$7.6 million in 2025, then soared by 100.63% to $48000.0 in 2026.
- Business Quant data shows NUVB's Capital Expenditures at $48000.0 in Q1 2026, -$7.6 million in Q4 2025, and $8.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Nuvation Bio | 2.38 Bn | 2.38 Bn | 30.78 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -3.78 Mn |
| Sep 30, 2025 | 7.75 Mn |
| Jun 30, 2025 | 398,000.00 |
| Mar 31, 2025 | -145,000.00 |
| Dec 31, 2024 | 5.86 Mn |
| Sep 30, 2024 | -313,000.00 |
| Mar 31, 2024 | 488,000.00 |
| Sep 30, 2023 | 553,000.00 |
| Jun 30, 2023 | 22,000.00 |
| Mar 31, 2023 | 12,000.00 |
| Dec 31, 2022 | 65,000.00 |
| Sep 30, 2022 | 103,000.00 |
| Jun 30, 2022 | 195,000.00 |
| Mar 31, 2022 | 7,000.00 |
| Dec 31, 2021 | 135,000.00 |
| Sep 30, 2021 | 29,000.00 |
| Jun 30, 2021 | 4,000.00 |
| Mar 31, 2021 | 114,000.00 |
| Dec 31, 2020 | 27,000.00 |
| Sep 30, 2020 | 15,000.00 |